Titan Pharmaceuticals, Inc. (TTNP)
- Previous Close
6.55 - Open
6.65 - Bid --
- Ask --
- Day's Range
6.56 - 6.65 - 52 Week Range
5.00 - 16.60 - Volume
992 - Avg. Volume
6,986 - Market Cap (intraday)
5.999M - Beta (5Y Monthly) 1.33
- PE Ratio (TTM)
-- - EPS (TTM)
-7.41 - Earnings Date Apr 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.
www.titanpharm.comRecent News: TTNP
Performance Overview: TTNP
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TTNP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TTNP
Valuation Measures
Market Cap
6.17M
Enterprise Value
-28.59k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.07k
Price/Book (mrq)
0.93
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-74.90%
Return on Equity (ttm)
-139.14%
Revenue (ttm)
184k
Net Income Avi to Common (ttm)
-5.57M
Diluted EPS (ttm)
-7.41
Balance Sheet and Cash Flow
Total Cash (mrq)
6.76M
Total Debt/Equity (mrq)
8.51%
Levered Free Cash Flow (ttm)
-5.65M
Research Analysis: TTNP
Company Insights: TTNP
TTNP does not have Company Insights